NIH Director Page NIH Health Information Page NIH Impact NIH Fact Sheets NIH Social Media and Outreach
EurekAlert! - National Institutes of Health  
LINKS

Resources

 

NIH Main

 

NIH Research News

 

Funded News

 
  For News & Research
  NIH Videos
  eColumn: NIH Research Matters
  NIH News in Health
  NIH Fact Sheets
 
  Additional Resources
  NIH Home Page
 

About NIH

  NIH Health Information
  Pub Med
  MedlinePlus
  Clinical trials.gov
  More News and Events Sources
  NIH News and Events, Special Interest
 
  RSS Feed RSS Feed
  Back to EurekAlert!
 

 


Department of Health and Human Services

News from the National Institutes of Health

NIH Research News


Key: Meeting M      Journal J      Funder F

Showing releases 76-84 out of 84.

<< < 1 | 2 | 3 | 4

Public Release: 17-Oct-2014
Using social media to better understand, prevent, and treat substance use
More than $11 million over three years will be used to support research exploring the use of social media to advance the scientific understanding, prevention, and treatment of substance use and addiction. The awards are funded through the Collaborative Research on Addiction at NIH, an NIH consortium involving NIAAA, NIDA and NCI.
NIH/National Institute on Alcohol Abuse and Alcoholism, NIH/National Institute on Drug Abuse, NIH/National Cancer Institute

Contact: NIDA Press Office
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse

Public Release: 15-Oct-2014
NIH grants license agreement for candidate Ebola vaccines
NIAID today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. The vaccines were created by scientists at NIAID and Thomas Jefferson University in Philadelphia and are being further developed through a partnership with the German pharmaceutical company IDT Biologika. The candidate vaccines now have been licensed to Exxell BIO of Saint Paul, Minnesota, which aims to advance the products through clinical testing and commercialization.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 14-Oct-2014
Journal of Neuroscience
Scientists sniff out unexpected role for stem cells in the brain
For decades, scientists thought that neurons in the brain were born only during the early development period and could not be replenished. More recently, however, they discovered cells with the ability to divide and turn into new neurons in specific brain regions. Scientists at the National Institutes of Health report that newly formed brain cells in the mouse olfactory system -- the area that processes smells -- play a critical role in maintaining proper connections.
National Institutes of Health Intramural Program

Contact: Barbara McMakin
nindspressteam@ninds.nih.gov
NIH/National Institute of Neurological Disorders and Stroke

Public Release: 8-Oct-2014
NIH funds research consortia to study more than 200 rare diseases
Physician scientists at 22 consortia will collaborate with representatives of 98 patient advocacy groups to advance clinical research and investigate new treatments for patients with rare diseases. The collaborations are made possible through awards by the National Institutes of Health -- totaling about $29 million in fiscal year 2014 funding -- to expand the Rare Diseases Clinical Research Network, which is led by NIH's National Center for Advancing Translational Sciences.
National Institutes of Health, NIH/National Center for Advancing Translational Sciences, NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/National Cancer Institute, NIH/National Heart, Lung and Blood Institute

Contact: Bobbi Gardner
bobbi.gardner@nih.gov
301-435-0888
NIH/National Center for Advancing Translational Sciences (NCATS)

Public Release: 8-Oct-2014
Science
NIH-supported scientists unveil structure, dynamics of key HIV molecules
New research has illuminated the movement and complete structure of the spikes on HIV that the virus uses to bind to the cells it infects. This research, led by scientists at the National Institutes of Health, Weill Cornell Medical College and Yale University School of Medicine, could help advance efforts to develop HIV vaccines and treatments.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 8-Oct-2014
JAMA Psychiatry
Increased health risks linked to first-episode psychosis
Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness. Patients with schizophrenia are already known to have higher rates of premature death than the general population. Elevated risks of heart disease and metabolic issues such as high blood sugar in people with first episode psychosis are due to an interaction of mental illness, unhealthy lifestyle behaviors and antipsychotic medications that may accelerate these risks.
NIH/National Institute of Mental Health

Contact: Michaelle Scanlon
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health

Public Release: 8-Oct-2014
New England Journal of Medicine
Gene therapy shows promise for severe combined immunodeficiency
Researchers have found that gene therapy using a modified delivery system, or vector, can restore the immune systems of children with X-linked severe combined immunodeficiency (SCID-X1), a rare, life-threatening inherited condition that primarily affects boys.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 7-Oct-2014
JAMA
Candidate H7N9 avian flu vaccine works better with adjuvant
An experimental vaccine to protect people against H7N9 avian influenza prompted immune responses in 59 percent of volunteers who received two injections at the lowest dosage tested, but only if the vaccine was mixed with adjuvant -- substance that boosts the body's response to vaccination. Without adjuvant, immune responses produced by the investigational vaccine were minimal regardless of vaccine dosage, according to findings from a clinical trial sponsored by NIAID, part of NIH.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 2-Oct-2014
HHS releases 13th Report on Carcinogens
Four substances have been added in the US Department of Health and Human Services 13th Report on Carcinogens, a science-based document that identifies chemical, biological, and physical agents that are considered cancer hazards for people living in the United States. The new report includes 243 listings.
National Institute of Environmental Health Sciences, National Toxicology Program

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences

Showing releases 76-84 out of 84.

<< < 1 | 2 | 3 | 4

     
   

HOME    DISCLAIMER    PRIVACY POLICY    CONTACT US
Copyright ©2015 by AAAS, the science society.